DEVELOPMENT pipeline
Reinvesting our profit to discover new medicines
At Servier, we choose to reinvest our profit to discover new medicines. Our development pipeline offers a tangible reflection of this commitment. Over recent years, it has expanded to comprise 70 projects, 41 of which in development and 29 research projects.
This innovative pipeline currently offers considerable potential for the Group to differentiate itself and create value, with 50% of projects deemed to be first in class.
Oncology
SOLID TUMORS
Vorasidenib
S95032
Solid tumors
Ivosidenib
S95031
Solid tumors (new indication)
Anti-MET
S95027
Non small Cell Lung Cancer
Vorasidenib + pembrolizumab
S95032
Solid tumors
Ivosidenib combo
S95031
Solid tumors (new indication)
Anti-TIM3 combo
S95018
Solid tumors
Anti-CD73 combo
S95024
Solid tumors
Anti-PD-L1/4-1BB
S95012
Solid tumors
Anti-NKG2A combo
S95029
Solid tumors
MAT2A inhibitor
S95035
Solid tumors
HEMATOLOGICAL MALIGNANCIES
Ivosidenib + 7+3 (chimio)
S95031
Hematological malignancies (new indication)
Calaspargase pegol combo
S95015
Hematological malignancies (new indication)
ND
S227928
Hematological malignancies
Neuroscience
LRRK2 inhibitor
S221237
Parkinson’s Disease
ND
S230815
Neurodevelopmental disorder
Immuno-inflammation
ND
S95041
Autoimmune disease
ND
S95042
Autoimmune disease
ND
S95044
Autoimmune disease
PCD= Preclinical development phase, 1 = Phase 1, 2 = Phase 2, 3 = Phase 3, ND= Not disclosed